Full Committee Review FCR NIH Guidelines for Research involving Recombinant or Synthetic nucleic acids NIH Guidelines April 2019 Designated Member Review DMR Biosafety Review Bio Administrative Review ID: 1009835
Download Presentation The PPT/PDF document "IBC LEVELS OF REVIEW (April 18, 2018)" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. IBC LEVELS OF REVIEW (April 18, 2018)Full Committee Review (FCR)NIH Guidelines for Research involving Recombinant or Synthetic nucleic acids (NIH Guidelines, April 2019)Designated Member Review (DMR)Biosafety Review (Bio)Administrative ReviewNewNIH Guidelines IIIA- IIIDRisk Group (RG)2 , RG3 and RG4 agents and materials potentially infected with RG2, RG3 and RG4Non human primate materials including fluids/tissues/organsAnimals/Arthropods that are natural reservoirs/vectors of zoonotic diseasesUse of Botulinum neurotoxin at any amountUse of Select toxin above permissible amountNIH Guidelines IIIE (with approval at IBC meeting) Use of Select Toxin, (except Botulinum neurotoxin) below permissible amount Primary human materials including tissues and organsNIH Guidelines IIIFHuman blood, bodily fluidEstablished human and non human primate cells onlyNon-rDNA at BSL1Addition/Removal of personnelChange in Faculty Sponsor Change in Funding Removal of location (Consult with Biosafety)Change in PI RenewalNIH Guidelines IIIA- IIIDRisk Group (RG)2 , RG3 and RG4 agents and materials potentially infected with RG2, RG3 and RG4Non human primate materials including fluids/tissues/organsAnimals/Arthropods that are natural reservoirs/vectors of zoonotic diseasesUse of Botulinum neurotoxin at any amountUse of Select toxin above permissible amountNIH Guidelines IIIE (with approval at IBC meeting) Use of exempt Select Toxin except Botulinum neurotoxinPrimary human materials including tissues and organsNIH Guidelines IIIFHuman blood, bodily fluidEstablished human and non human primate cells onlyNon-rDNA at BSL1ModificationAll applications above that fall under different NIH Guidelines (IIIA- IIID) All modifications (except changes in location, personnel, number of subjects enrolled, statistical analysis) in HGT application (IIIC)All modification involving RG 3 and RG4Change in procedures/materials/host/agent that result in higher risk ( eg. purchasing lentivirus from outside vendor versus growing lentivirus in the lab, using aerosol transmissible pathogen versus bloodborne pathogen, using modified agent that is amphotrophic versus ecotrophic, using sheep for heart transplant versus mice)IIIE (with approval at IBC meeting) that is different from approved applicationPrimary human materials that might have different risk from currently approved onesNIH Guidelines IIIFIIID that meets the following criteria 1) currently approved under the same applicable guideline 2) has the same risk (eg. Adding different reporter gene in Lentiviral vector, carrying out same experiments in mice versus rats, adding RG2s that have the same risk as currently approved ones) 3) has same NIH guidelines requirementsAddition of new location